Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

431P - Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)

Date

14 Sep 2024

Session

Poster session 15

Topics

Tumour Site

Breast Cancer

Presenters

Hope Rugo

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

H.S. Rugo1, A. Bardia2, S. Im3, S. Pernas Simon4, M. De Laurentiis5, S. Wang6, N. Martinez7, G. Santos Borges8, D. Cescon9, M. Hattori10, Y. Lu11, J. Tsurutani12, S.M. Tolaney13, D. Mapiye14, K. Atuah15, D. Verma16, S. Khan17, B. Xu18, B. Pistilli19, K. Jhaveri20

Author affiliations

  • 1 Department Of Medicine, University of California San Francisco Comprehensive Cancer Center, 94115 - San Francisco/US
  • 2 Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles/US
  • 3 Department Of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul/KR
  • 4 Department Of Medical Oncology, Institut Català d'Oncologia, IDIBELL, L’Hospitalet, Barcelona/ES
  • 5 Department Of Breast And Thoracic Oncology, Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", 80131 - Napoli/IT
  • 6 Department Of Medical Oncology, Cancer Center of Sun Yat-sen University, 510060 - Guangzhou/CN
  • 7 Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28031 - Madrid/ES
  • 8 Clinical Oncology, Catarina Pesquisa Clínica, Santa Catarina/BR
  • 9 Department Of Medical Oncology, Princess Margaret Cancer Centre/UHN, M5G 1Z5 - Toronto/CA
  • 10 Department Of Breast Oncology, Aichi Cancer Center, 464-8681 - Nagoya/JP
  • 11 Department Of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, 10002 - Taipei/TW
  • 12 Advanced Cancer Translational Research Institute, Showa University, 142-8555 - Shinagawa-ku/JP
  • 13 Division Of Breast Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 14 Biostatistics, Astrazeneca, - - Cambridge/GB
  • 15 Global Patient Safety, AstraZeneca, CB21 6GH - Cambridge/GB
  • 16 Oncology R&d Late Stage Clinical Development, AstraZeneca, CB2 0AA - Cambridge/GB
  • 17 Oncology R&d Late Stage Clinical Development, AstraZeneca, 20878 - Gaithersburg/US
  • 18 ., National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 19 Department Of Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 20 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 431P

Background

In TROPION-Breast01 (TB-01; NCT05104866), the antibody-drug conjugate Dato-DXd showed improved efficacy vs ICC in pts with HR+/HER2– BC [Bardia et al. ESMO 2023]. The Dato-DXd safety profile was manageable. The most common treatment (Tx)-related AEs (TRAEs) were nausea and stomatitis; ICC was notable for high rates of grade 3/4 neutropenia. Here we report an analysis of EAIRs of AEs in the context of the longer Tx duration with Dato-DXd vs ICC (median 6.7 vs 4.1 mo).

Methods

The TB-01 study design was previously described. EAIRs were derived from a post-hoc analysis and were expressed as subject rate (per 100 pt yrs) and calculated as number of pts with AEs divided by the total duration of Tx across all pts per group (see Table) x 100.

Results

Absolute incidence rates of TRAEs with Dato-DXd were 93.6% and 86.3% with ICC; Dato-DXd had less than half the proportion of G≥3 TRAEs vs ICC. Other absolute incidence rates with Dato-DXd, including Tx-related serious AEs (TRSAEs) and TRAEs leading to Tx discontinuation, were lower than or similar to ICC. However, EAIRs were lower for Dato-DXd vs ICC across all such summary AE categories, illustrating that the longer Dato-DXd Tx duration did not impact AE incidence rates per 100 pt yrs (Table). For the most frequent TEAEs with absolute incidence ≥5% in both arms, EAIRs ≥2x higher with ICC vs Dato-DXd were neutropenia (63 vs 9; ratio 6.9:1), decreased neutrophil count (55 vs 12; 4.7:1), diarrhea (47 vs 19; 2.4:1), anemia (61 vs 28; 2.2:1) and headache (27 vs 13; 2.1:1). In the Dato-DXd arm, only stomatitis was ≥2x higher vs ICC (93 vs 36; 2.6:1). Table: 431P

Safety summary of absolute incidence and EAIRs – All Investigator-assessed*

Dato-DXd (N=360) ICC (N=351)
Total Tx duration, yrs 197.7 140.6
TRAEs
n (%) 337 (93.6) 303 (86.3)
Subject rate (per 100 pt yrs) 170.49 215.55
Grade ≥3 TRAEs
n (%) 75 (20.8) 157 (44.7)
Subject rate (per 100 pt yrs) 37.94 111.69
TRSAEs
n (%) 21 (5.8) 32 (9.1)
Subject rate (per 100 pt yrs) 10.62 22.76
TX-related deaths
n (%) 0 1 (0.3)
Subject rate (per 100 pt yrs) 0 0.71
TRAEs leading to Tx discontinuation
n (%) 9 (2.5) 9 (2.6)
Subject rate (per 100 pt yrs) 4.55 6.40

Data cutoff 17 July 2023. *EAIRs expressed as subject rate (per 100 pt yrs).

Conclusions

After adjusting for Tx duration, Dato-DXd is more tolerable vs ICC across all AE categories and for a majority of individual AEs, further emphasising the potential for Dato-DXd as a well tolerated Tx option.

Clinical trial identification

NCT05104866, Release date: 3 Nov 2021.

Editorial acknowledgement

Medical writing support for the development of this abstract, under the direction of the authors, was provided by Catherine Crookes of Ashfield MedComms (Macclesfield, UK), an Inizio company, and was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca PLC in collaboration with Daiichi Sankyo.

Funding

AstraZeneca PLC in collaboration with Daiichi Sankyo.

Disclosure

H.S. Rugo: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Napo Pharmaceuticals, Puma Biotechnology, Mylan, Daiichi Sankyo; Financial Interests, Institutional, Funding, Research funding (to institution): OBI Pharma, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Astellas Pharma, Taiho Oncology, Veru, GSK, Genentech/Roche, Stemline Therapeutics. A. Bardia: Financial Interests, Personal, Advisory Role, Consulting or advisory role (personal): Novartis, Genentech, Pfizer, Merck, Sanofi, Daiichi Sankyo, AstraZeneca, Lilly, Gilead Sciences, Menarini, Mersana; Financial Interests, Institutional, Advisory Role, Consulting or advisory role (to institution): Novartis, Genetech/Roche, Pfizer, Radius Health, Innocrin Pharma, Lilly, Gilead Sciences, Menarini; Financial Interests, Institutional, Funding, Research funding (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, AstraZeneca, Daiichi Sankyo. S. Im: Financial Interests, Personal, Advisory Role, Consulting or advisory role: AstraZeneca, Novartis, Roche/Genentech, Eisai, Pfizer, Amgen, Hanmi, Lilly, MSD, Daiichi Sankyo; Financial Interests, Institutional, Funding, Research funding (to institution): AstraZeneca, Pfizer, Roche/Genentech, Daewoong Pharmaceutical, Eisai, Boryung Pharmaceuticals. S. Pernas Simon: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Seagen, Pfizer, Pierre Fabre, Daiichi Sankyo/AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Novartis, Lilly, Roche, Gilead Sciences, Pfizer, Daiichi Sankyo/AstraZeneca; Financial Interests, Personal, Other, Travel, accommodation, expenses: Gilead Sciences, AstraZeneca, Roche, Pfizer; Financial Interests, Institutional, Funding, Research funding (to institution): Roche. M. De Laurentiis: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Novartis, Eli Lilly, Pfizer, Roche, Sanofi, MSD, Seagen, Gilead, Exact Science, Daiichi Sankyo, AstraZeneca, Eisai; Financial Interests, Institutional, Principal Investigator: Novartis, Eli Lilly, Pfizer, Roche, Sanofi, MSD, Seagen, Gilead, Daiichi Sankyo, AstraZeneca, Eisai. S. Wang: Financial Interests, Personal, Advisory Role, Consulting or advisory role: AstraZeneca, Daiichi Sankyo; Financial Interests, Institutional, Funding, Research funding: AstraZeneca. N. Martinez: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Novartis, Lilly, Pfizer, Roche, Seagen, Gilead, Daiichi Sankyo, AstraZeneca, Eisai; Financial Interests, Institutional, Principal Investigator: Novartis, Eli Lilly, Pfizer, Roche, Sanofi, MSD, Seagen, Gilead, Daiichi Sankyo, AstraZeneca, Eisai. G. Santos Borges: Non-Financial Interests, Personal, Principal Investigator: TROPION-Breast01 (uncompensated). D. Cescon: Financial Interests, Personal, Advisory Role, Consulting or advisory role: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, GSK, Inflex, Inivata/NeoGenomics, Lilly, Merck, Novartis, Pfizer, Roche, Saga; Financial Interests, Institutional, Funding, Research funding to institution: AstraZeneca, Guardant Health, Gilead, GSK, Inivata/NeoGenomics, Knight, Merck, Pfizer, ProteinQure, Roche; Financial Interests, Personal, Royalties, For methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene: Patent: US62/675,228. M. Hattori: Financial Interests, Personal, Advisory Role, Honoraria: Chugai Pharma, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD K.K. Y. Lu: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Pfizer, Roche, Novartis, Lilly; Financial Interests, Personal, Other, Travel, accommodation, expenses: Novartis; Financial Interests, Personal, Advisory Role, Honoraria: Pfizer, Roche, MSD, Novartis, Lilly, Eisai, Daiichi Sankyo/UCB Japan, AstraZeneca, EuroPharma; Financial Interests, Institutional, Funding, Research funding (to institution): Novartis, MSD, AstraZeneca. J. Tsurutani: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Daiichi Sankyo, Lilly, AstraZeneca, Seagen; Financial Interests, Personal, Advisory Role, Honoraria: Kyowa Kirin, Eisai, Chugai Pharma, Taiho Pharmaceutical, Nihonkayaku, Lilly Japan, Daiichi Sankyo, Pfizer; Financial Interests, Institutional, Funding, Research funding (to institution): ): Eisai, Boehringer Ingelheim, Lilly, MSD Oncology, Kyowa Kirin, Daiichi Sankyo, Chugai Pharma, Nihonkayaku, West Japan Oncology Group, Sant Joan de Déu Research Foundation (FSJD). S.M. Tolaney: Financial Interests, Personal, Advisory Role, Consulting or advisory Role: Novartis, Pfizer (Seagen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, ; Financial Interests, Institutional, Funding, Research Funding (to institution): Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Gilead, Seattle Genetics, OncoPep, Daiichi Sankyo; Financial Interests, Personal, Other, Travel: Eli Lilly, Sanofi, Gilead, Jazz Pharmaceuticals. D. Mapiye: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. K. Atuah; D. Verma; S. Khan: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. B. Xu: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Pfizer, Roche; Financial Interests, Personal, Advisory Role, Consulting or advisory role: AstraZeneca, Novartis. B. Pistilli: Financial Interests, Institutional, Advisory Role, Consulting fees (institutional): AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, Daiichi Sankyo; Financial Interests, Personal, Advisory Role, Consulting fees (personal): Pierre Fabre, Daiichi Sankyo; Financial Interests, Institutional, Funding, Institutional research funding: AstraZeneca, Daiichi Sankyo, Gilead, Seagen, MSD; Financial Interests, Personal, Other, Travel support: AstraZeneca, Pierre Fabre, Lilly, Daiichi Sankyo, MSD. K. Jhaveri: Financial Interests, Personal, Advisory Role, Consulting or advisory role: Novartis, Pfizer, AstraZeneca, Jounce Therapeutics, Synthon, Intellisphere, BMS, Genentech, AbbVie, Lilly, BluePrint Medicines, Seagen, Daiichi Sankyo, Biotheranostics, Sun Pharma Advanced Research Company, Taiho Oncology, Sanofi, Gilead Sciences, Scorpio; Financial Interests, Personal, Other, Travel, accommodation, expenses: Taiho Pharmaceutical, Jounce Therapeutics, Pfizer, AstraZeneca, Intellisphere, Lilly, Gilead Sciences, Genentech/Roche; Financial Interests, Institutional, Funding, Research funding (to institution): Novartis, Genentech, Debiopharm Group, ADC Therapeutics, Pfizer, Novita Pharmaceuticals, Clovis Oncology, Lilly, Zymeworks, Immunomedics, Puma Biotechnology, VelosBio/Merck, AstraZeneca, Context Therapeutics, Scorpion Therapeutics, Blueprint Medicines.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.